Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).

@article{Duerr2012ExtendedFC,
  title={Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).},
  author={Ann C Duerr and Yunda Huang and Susan P Buchbinder and Robert W. Coombs and Jorge S{\'a}nchez and Carlos Del Rio and Mart{\'i}n Casap{\'i}a and Steven Santiago and Peter Gilbert and Lawrence Corey and Michael N. Robertson},
  journal={The Journal of infectious diseases},
  year={2012},
  volume={206 2},
  pages={258-66}
}
BACKGROUND The Step Study tested whether an adenovirus serotype 5 (Ad5)-vectored human immunodeficiency virus (HIV) vaccine could prevent HIV acquisition and/or reduce viral load set-point after infection. At the first interim analysis, nonefficacy criteria were met. Vaccinations were halted; participants were unblinded. In post hoc analyses, more HIV infections occurred in vaccinees vs placebo recipients in men who had Ad5-neutralizing antibodies and/or were uncircumcised. Follow-up was… CONTINUE READING